Tetrahedral Framework Nucleic Acid Relieves Sepsis-Induced Intestinal Injury by Regulating M2 Macrophages

Abstract

This study aimed to clarify the role and mechanism of tetrahedral framework nucleic acids (tFNAs) in regulating M2 macrophages to reduce intestinal injury. An intestinal injury model was established by intraperitoneal injection of lipopolysaccharides (LPS) in mice to explore the alleviating effects of tFNAs on intestinal injury. Inflammatory factors were detected by quantitative polymerase chain reaction (qPCR) and enzyme-linked immunosorbent assay (ELISA). The intestinal barrier and permeability were assessed using western blotting and immunohistochemistry. Macrophages in the gut were localised and quantified using immunofluorescence. Western blotting was used to investigate the role and mechanism of tFNAs in regulating macrophages and alleviating inflammation in the injured intestines. These results show that tFNAs attenuated sepsis-induced intestinal injury. tFNAs can also promote the intestinal barrier reconstruction and reduce intestinal permeability. In vivo, tFNAs accelerated the aggregation of M2 macrophages at an early stage of injury and reduced the number of M1 macrophages in the intestine. In addition, tFNAs enhanced the clearance ability of intestinal macrophages. They activated the signalling and transcription activating factor 1(STAT1) and cytokine signalling inhibitory factor 1/3 (SOCS1/3) pathways by increasing the expression of the phagocytic receptor Mertk. These findings indicated that tFNAs can alleviate sepsis-induced intestinal injury by regulating M2 macrophages, providing a new option for treating intestinal injury.

References

[1] N. J. Klingensmith and C. M. Coopersmith, “The Gut as the Motor of Multiple Organ Dysfunction in Critical Illness,” Critical Care Clinics 32, no. 2 (2016): 203-212.

[2] T. T. Chen, J. J. Lv, L. Chen, M. Li, and L. P. Liu, “Heparanase Inhibition Leads to Improvement in Patients With Acute Gastrointestinal Injuries Induced by Sepsis,” World Journal of Gastroenterology 29, no. 35 (2023): 5154-5165.

[3] A. Reintam Blaser, M. L. Malbrain, J. Starkopf, et al., “Gastrointestinal Function in Intensive Care Patients: Terminology, Definitions and Management. Recommendations of the ESICM Working Group on Abdominal Problems,” Intensive Care Medicine 38, no. 3 (2012): 384-394.

[4] K. E. Rudd, S. C. Johnson, K. M. Agesa, et al., “Global, Regional, and National Sepsis Incidence and Mortality, 1990-2017: Analysis for the Global Burden of Disease Study,” Lancet 395, no. 10219 (2020): 200-211.

[5] M. Cecconi, L. Evans, M. Levy, and A. Rhodes, “Sepsis and Septic Shock,” Lancet 392, no. 10141 (2018): 75-87.

[6] A. Rhodes, L. E. Evans, W. Alhazzani, et al., “Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016,” Intensive Care Medicine 43, no. 3 (2017): 304-377.

[7] J. E. Gotts and M. A. Matthay, “Sepsis: Pathophysiology and Clinical Management,” British Medical Journal 353 (2016): i1585.

[8] B. Guery and T. Calandra, “Early Antimicrobial Therapy for Sepsis: Does Each Hour Really Count?,” Seminars in Respiratory and Critical Care Medicine 40, no. 4 (2019): 447-453.

[9] Y. R. Na, M. Stakenborg, S. H. Seok, and G. Matteoli, “Macrophages in Intestinal Inflammation and Resolution: A Potential Therapeutic Target in IBD,” Nature Reviews. Gastroenterology & Hepatology 16, no. 9 (2019): 531-543.

[10] T. C. Moreira Lopes, D. M. Mosser, and R. Gonçalves, “Macrophage Polarization in Intestinal Inflammation and Gut Homeostasis,” Inflammation Research 69, no. 12 (2020): 1163-1172.

[11] T. van der Poll, F. L. van de Veerdonk, B. P. Scicluna, and M. G. Netea, “The Immunopathology of Sepsis and Potential Therapeutic Targets,” Nature Reviews. Immunology 17, no. 7 (2017): 407-420.

[12] C. V. Rothlin, E. A. Carrera-Silva, L. Bosurgi, and S. Ghosh, “TAM Receptor Signaling in Immune Homeostasis,” Annual Review of Immunology 33 (2015): 355-391.

[13] D. DeRyckere, J. M. Huelse, H. S. Earp, and D. K. Graham, “TAM Family Kinases as Therapeutic Targets at the Interface of Cancer and Immunity,” Nature Reviews. Clinical Oncology 20, no. 11 (2023): 755-779.

[14] C. V. Rothlin, S. Ghosh, E. I. Zuniga, M. B. Oldstone, and G. Lemke, “TAM Receptors Are Pleiotropic Inhibitors of the Innate Immune Response,” Cell 131, no. 6 (2007): 1124-1136.

[15] J. P. Vago, F. A. Amaral, and F. A. J. van de Loo, “Resolving Inflammation by TAM Receptor Activation,” Pharmacology & Therapeutics 227 (2021): 107893.

[16] H. Wu, J. Zheng, S. Xu, et al., “Mer Regulates Microglial/Macrophage M1/M2 Polarization and Alleviates Neuroinflammation Following Traumatic Brain Injury,” Journal of Neuroinflammation 18, no. 1 (2021): 2.

[17] L. Bosurgi, J. H. Bernink, V. Delgado Cuevas, et al., “Paradoxical Role of the Proto-Oncogene Axl and Mer Receptor Tyrosine Kinases in Colon Cancer,” Proceedings of the National Academy of Sciences of the United States of America 110, no. 32 (2013): 13091-13096.

[18] Y. R. Miao, E. B. Rankin, and A. J. Giaccia, “Therapeutic Targeting of the Functionally Elusive TAM Receptor Family,” Nature Reviews. Drug Discovery 23, no. 3 (2024): 201-217.

[19] Z. Wang, H. Lu, T. Tang, et al., “Tetrahedral Framework Nucleic Acids Promote Diabetic Wound Healing via the Wnt Signalling Pathway,” Cell Proliferation 55, no. 11 (2022): e13316.

[20] D. Xiao, Y. Li, T. Tian, et al., “Tetrahedral Framework Nucleic Acids Loaded With Aptamer AS1411 for siRNA Delivery and Gene Silencing in Malignant Melanoma,” American Chemical Society Applied Materials & Interfaces 13, no. 5 (2021): 6109-6118.

[21] X. Chen, J. He, Y. Xie, et al., “Tetrahedral Framework Nucleic Acid Nanomaterials Reduce the Inflammatory Damage in Sepsis by Inhibiting Pyroptosis,” Cell Proliferation 56, no. 8 (2023): e13424.

[22] Y. Wang, Y. Li, S. Gao, X. Yu, Y. Chen, and Y. Lin, “Tetrahedral Framework Nucleic Acids Can Alleviate Taurocholate-Induced Severe Acute Pancreatitis and Its Subsequent Multiorgan Injury in Mice,” Nano Letters 22, no. 4 (2022): 1759-1768.

[23] S. Li, T. Tian, T. Zhang, Y. Lin, and X. Cai, “A Bioswitchable Delivery System for microRNA Therapeutics Based on a Tetrahedral DNA Nanostructure,” Nature Protocolss41596-024-01050-7 (2024).

[24] X. Chen, Z. Xu, Y. Gao, et al., “Framework Nucleic Acid-Based Selective Cell Catcher for Endogenous Stem Cell Recruitment,” Advanced Materials 36, no. 50 (2024): e2406118.

[25] F. Meng, J. Wang, and Y. Yeo, “Nucleic Acid and Oligonucleotide Delivery for Activating Innate Immunity in Cancer Immunotherapy,” Journal of Controlled Release 345 (2022): 586-600.

[26] W. Cui, Z. Guo, X. Chen, et al., “Targeting Modulation of Intestinal Flora Through Oral Route by an Antimicrobial Nucleic Acid-Loaded Exosome-Like Nanovesicles to Improve Parkinson's Disease,” Sci Bull (Beijing) 69 (2024): 3925-3935.

[27] Y. Li, Z. Cai, W. Ma, L. Bai, E. Luo, and Y. Lin, “A DNA Tetrahedron-Based Ferroptosis-Suppressing Nanoparticle: Superior Delivery of Curcumin and Alleviation of Diabetic Osteoporosis,” Bone Research 12, no. 1 (2024): 14.

[28] J. Li, Y. Yao, Y. Wang, et al., “Modulation of the Crosstalk Between Schwann Cells and Macrophages for Nerve Regeneration: A Therapeutic Strategy Based on a Multifunctional Tetrahedral Framework Nucleic Acids System,” Advanced Materials 34, no. 46 (2022): e2202513.

[29] L. Yao, G. Zhang, Y. Wang, et al., “Development of an Inhalable DNA Tetrahedron MicroRNA Sponge,” Advanced Materials 22 (2024): e2414336.

[30] B. Xie, M. Wang, X. Zhang, et al., “Gut-Derived Memory γδ T17 Cells Exacerbate Sepsis-Induced Acute Lung Injury in Mice,” Nature Communications 15, no. 1 (2024): 6737.

[31] S. Seemann, F. Zohles, and A. Lupp, “Comprehensive Comparison of Three Different Animal Models for Systemic Inflammation,” Journal of Biomedical Science 24, no. 1 (2017): 60.

[32] A. T. Blikslager, A. J. Moeser, J. L. Gookin, S. L. Jones, and J. Odle, “Restoration of Barrier Function in Injured Intestinal Mucosa,” Physiological Reviews 87, no. 2 (2007): 545-564.

[33] A. S. Luis and G. C. Hansson, “Intestinal Mucus and Their Glycans: A Habitat for Thriving Microbiota,” Cell Host & Microbe 31, no. 7 (2023): 1087-1100.

[34] M. Cecconi, D. De Backer, M. Antonelli, et al., “Consensus on Circulatory Shock and Hemodynamic Monitoring. Task Force of the European Society of Intensive Care Medicine,” Intensive Care Medicine 40, no. 12 (2014): 1795-1815.

[35] C. V. Rothlin, J. A. Leighton, and S. Ghosh, “Tyro3, Axl, and Mertk Receptor Signaling in Inflammatory Bowel Disease and Colitis-Associated Cancer,” Inflammatory Bowel Diseases 20, no. 8 (2014): 1472-1480.

[36] A. M. Mowat and W. W. Agace, “Regional Specialization Within the Intestinal Immune System,” Nature Reviews. Immunology 14, no. 10 (2014): 667-685.

[37] L. W. Peterson and D. Artis, “Intestinal Epithelial Cells: Regulators of Barrier Function and Immune Homeostasis,” Nature Reviews. Immunology 14, no. 3 (2014): 141-153.

[38] P. Li, L. Fu, C. Ning, et al., “Effect of Tetrahedral Framework Nucleic Acids on the Reconstruction of Tendon-To-Bone Injuries After Rotator Cuff Tears,” Cell Proliferation 57, no. 6 (2024): e13605.

[39] J. Van den Bossche, J. Baardman, N. A. Otto, et al., “Mitochondrial Dysfunction Prevents Repolarization of Inflammatory Macrophages,” Cell Reports 17, no. 3 (2016): 684-696.

[40] S. Tacconi, F. Vari, C. Sbarigia, et al., “M1-Derived Extracellular Vesicles Polarize Recipient Macrophages Into M2-Like Macrophages and Alter Skeletal Muscle Homeostasis in a Hyper-Glucose Environment,” Cell Communication and Signaling: CCS 22, no. 1 (2024): 193.

[41] D. M. Mosser, K. Hamidzadeh, and R. Goncalves, “Macrophages and the Maintenance of Homeostasis,” Cellular & Molecular Immunology 18, no. 3 (2021): 579-587.

[42] M. Du and Z. J. Chen, “DNA-Induced Liquid Phase Condensation of cGAS Activates Innate Immune Signaling,” Science 361, no. 6403 (2018): 704-709.

[43] H. Wu, J. Lin, N. Ling, et al., “Functional Nucleic Acid-Based Immunomodulation for T Cell-Mediated Cancer Therapy,” American Chemical Society Nano 18, no. 1 (2024): 119-135.

[44] Y. Yang, J. Yang, J. Zhu, et al., “A DNA Tetrahedron-Based Nanosuit for Efficient Delivery of Amifostine and Multi-Organ Radioprotection,” Bioactive Materials 39 (2024): 191-205.

[45] C. Qi, Q. Sun, D. Xiao, et al., “Tetrahedral Framework Nucleic Acids/Hyaluronic Acid-Methacrylic Anhydride Hybrid Hydrogel With Antimicrobial and Anti-Inflammatory Properties for Infected Wound Healing,” International Journal of Oral Science 16, no. 1 (2024): 30.

[46] Y. Ge, Q. Wang, Y. Yao, et al., “Framework Nucleic Acids-Based VEGF Signaling Activating System for Angiogenesis: A Dual Stimulation Strategy,” Advanced Science 11, no. 21 (2024): e2308701.

[47] Q. Wang, J. Cheng, F. Liu, et al., “Modulation of Cerebrospinal Fluid Dysregulation via a SPAK and OSR1 Targeted Framework Nucleic Acid in Hydrocephalus,” Advanced Science 11, no. 17 (2024): e2306622.

[48] B. Long, M. Feng, Q. Zhang, et al., “Synergistic Osteogenic and Anti-Apoptotic Framework Nucleic Acid Complexes Prevent Diabetic Osteoporosis,” Advanced Functional Materials 2314789, no. 28 (2024): 2314789.

[49] Y. Chen, X. Chen, B. Zhang, et al., “DNA Framework Signal Amplification Platform-Based High-Throughput Immune-Cell Phenotyping System for Rapid Systemic Immune Monitoring,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 28.

RIGHTS & PERMISSIONS

2025 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.